#hypertension_vascular_health

Blood Pressure After 80: Treat the Patient, Not the Number

Medically Reviewed by Dr. Şekip Altunkan on Nov 19, 2026.
An internal medicine physician checks the standing blood pressure of an 86-year-old woman using a walker in a sunlit outpatient clinic to assess orthostatic hypotension and frailty. Illustration: Vitalsdaily

Image generated with AI · VitalsDaily

Key Takeaway:

The three leading hypertension guidelines across Europe and the United States agree that lowering blood pressure in older adults saves lives; however, they draw divergent boundaries regarding how aggressively targets should be pursued in the oldest-old. A new comparative review concludes that blood pressure management after age 80 must be personalized—grounded not in chronological age or an isolated measurement, but in formal assessments of physical function and frailty.

Two Patients, the Same Birth Year

Picture two 84-year-old women sitting in the same waiting room. Both have a blood pressure reading of 158/80 mmHg. The first walked to her appointment unassisted, still plays doubles tennis every Thursday, and takes only a single medication for cholesterol. The second arrived in a wheelchair, accompanied by her son. She takes nine daily medications, suffered two falls last winter, and experiences orthostatic dizziness every morning upon getting out of bed.

On paper, both patients appear to share the exact same clinical problem. In practice, they could not be more different—and applying the identical therapeutic strategy to both could cause serious harm to one. Elevated blood pressure represents the most common cardiovascular risk factor in older adults, serving as a primary driver of myocardial infarction, stroke, and overall mortality[2]. The core dilemma is that the patients most susceptible to treatment-related harms are almost invariably excluded from major clinical trials.

Three Guidelines, One Unresolved Dilemma

Gąsowski and colleagues set out to evaluate how three major contemporary guidelines navigate this clinical gray zone: the European Society of Hypertension (ESH, 2023–2024), the European Society of Cardiology (ESC, 2024), and the American Heart Association/American College of Cardiology (AHA/ACC, 2025). The work is a…

Medically reviewed by

Dr. Şekip Altunkan

Dr. Şekip Altunkan is an internal medicine specialist with extensive clinical experience. He trained at Hacettepe University Faculty of Medicine and later served as an Associate Professor in Internal Medicine. He founded and led the Metropol Internal Medicine and Hypertension Clinic in Ankara, pioneering non-invasive Electron Beam Tomography (EBT) cardiac imaging, arterial-stiffness measurement, and nationwide Holter monitoring. He currently practices at his private clinic in Ankara, focusing on hypertension, vascular health, cholesterol, diabetes and heart disease. He has published widely in national and international journals, serves as a peer reviewer for several international journals, and is the author of the book "Questions and Answers on Hypertension."

Share this article